Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 100
• 9 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-small cell lung cancer that has spread and/or cannot be removed by surgery, and whose cancer got worse after earlier treatment.

Age

18 years or older

Sex

Women and men can join.

Disease stage

Metastatic and/or unresectable non-small cell lung cancer (NSCLC).

Earlier treatment

The cancer got worse on at least one and not more than three earlier lines of treatment for metastatic or unresectable NSCLC.

Read by machine on 9 Nov 2026.

Sites (9)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details